Fig. 3From: Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison studyGlucose level over 24 h during treatment with oral semaglutide versus dipeptidyl peptidase 4 inhibitors. Continuous glucose monitoring (CGM) data at baseline a and after 24 weeks of intervention bBack to article page
